As the pharmaceutical industry continues to spend more on research and development, outsourcing clinical trials to CRO`s is becoming more common. This trend stems from technological advances, increasing costs of patents and generic medications, and a growing need for outsourcing pharmaceutical research services. In addition, the Covid-19 pandemic has caused a temporary halt in clinical trial activity, forcing some operations to evaluate new growth opportunities.
Vial CRO`s
Vial CRO`s is a multinational company that serves the combined industries of health information technology and clinical research. CRO`s is headquartered in the United States and provides research services to pharmaceutical companies and hospitals worldwide. It was established in 1992 and has since expanded globally.
Vial CRO is a leader in clinical trial analytics. Its big-data analytics help drive clinical trials for 85% of the world’s pharmaceutical companies. The company helps its clients with everything from designing clinical trials to identifying sites and recruiting patients. CRO`s also offers marketing services.
CRO`s have a global reach and provides clinical trials across a range of therapeutic areas. The company also provides data analytics for life sciences companies. With 55,000 employees and operations across 100 countries, Vial CRO is a leading contract research organization and data analytics provider. Here, it works with pharma and biotech clients to deliver actionable insights that can help drive change and innovation in the healthcare industry.
The company has an extensive database of anonymized health data. Its portfolio includes 1.2 billion non-identifiable patient records, 56 billion petabytes of proprietary data, and 150k data suppliers. This data helps companies accelerate clinical trials and reduce risk. It also helps to improve healthcare access and delivery.
The company says it has more than 5,000 clients in more than 100 countries. Most of its revenue comes from just one large client. However, the company says that it has experienced a spike in its revenue this year, which rose by 22% and its net profit more than doubled to $966 million.
ICON
ICON is a multinational, NASDAQ-listed clinical research organization. It provides consulting, clinical development, and commercialization services to the pharmaceutical industry. Headquartered in Ireland, ICON has 38,000 employees in 147 locations in 46 countries. ICON has the resources to handle the most complex clinical trials, ranging from preclinical studies to phase III clinical trials.
ICON provides a full range of services, including global site networks, innovative clinical trial methods, and commercial connected health platforms. Additionally, ICON offers expertise in home health and wearable technology. In addition, ICON offers advisory services in regulatory intelligence, drug development, and asset valuation. ICON also provides a wide array of clinical trial regulatory services.
ICON offers contract research services for biotech, pharmaceutical, and medical device companies. Its services span the clinical development lifecycle, from compound selection and Phase I-III studies to post-approval outcome research and market access consulting. These services help pharmaceutical companies bring new products to market faster. ICON conducts clinical trials in most major therapeutic areas, including gastrointestinal, cardiovascular, and oncology.
ICON is the preferred clinical research service provider for Pfizer Inc. Its CEO, Steve Cutler, has witnessed the evolution of the biopharma industry. Before joining ICON, he held various positions with Sandoz International GMBH, including COO. He also played for Australia in rugby, representing the country 40 times between 1982 and 1991.
ICON is committed to an inclusive, equal opportunity workplace. All qualified candidates will receive consideration for employment without regard to their race, religion, national origin, or disability.
PPD
PPD is a global clinical research organization with more than 30 years of experience. It provides services to pharmaceutical companies, nonprofit organizations, and governmental agencies around the world. With more than 26,000 employees in almost 50 countries, PPD is well positioned to provide solutions that accelerate drug development and accelerate clinical trials.
PPD’s innovative solutions are used in a variety of different settings, including remote clinical trials and custom clinical research. In addition, it uses cutting-edge eCOA and ePRO technologies to better share clinical trial data. These digital platforms reduce the need for paper documentation, provide more timely data, and improve consistency across studies.
PPD is a contract research organization that provides drug development and post-approval services to pharmaceutical and biotechnology companies. Its services include recruiting patients, managing trial sites, and providing various services that support the development and approval of new drugs. It generated $3.8 billion in revenue last year through its Clinical Development Services segment. It also offers Laboratory Services, which include testing samples for clinical trials.
PPD is among the biggest CRO`s in the world, with a market cap of $13 billion. However, it is not a perfect company. Last summer, it rejected a bid from Qiagen. But it still has $12.5 billion to spend on clinical research. It is expanding its network of research sites by forming strategic partnerships with Synexus and Radiant. PPD has more than 27,000 employees worldwide. In December 2021, it will become a wholly-owned subsidiary of Thermo Fisher Scientific.
Read also: Choosing the most appropriate child care center
Fisher Clinical Services
Providing global support for clinical trials, Fisher Clinical Services has more than 25 years of experience in clinical trial management. Its services include packaging, labeling, storage and distribution, import/export and ancillary supplies sourcing. With a team of 200 professionals globally, Fisher Clinical Services offers a variety of solutions to meet any clinical trial need. These services are available for clinical trials spanning all therapeutic areas.
The company’s Suzhou location provides a complete suite of services, including materials storage, label printing and packaging. Additionally, it has a facility for the storage of beta lactams, a molecule found in some cancer drugs. Suzhou also provides cold chain services for clinical trials.
Thermo Fisher’s global clinical research business supports clients with flexible decentralized trial solutions to increase patient diversity and improve patient experience. In addition, it supports responses technology systems and blinded trials. This allows customers to increase their geographic reach and increase the quality of clinical trial data. Its clinical trial services have served over 1,500 patients globally, treating a variety of diseases and conditions.
Fisher’s PPD clinical research business has over three decades of experience in providing clinical research services to nonprofits, governmental agencies and other organizations. These services span the globe and are vital to a number of different diseases, including cancer. Cancer is one of the most common causes of death worldwide. In fact, one out of six deaths worldwide is attributed to the disease. Additionally, 400,000 children are diagnosed with cancer every year.
With headquarters in Allentown, Pennsylvania, Fisher Clinical Services operates 16 purpose-built GMP/GDP-compliant facilities across five continents. These facilities offer flexibility and quality for clinical trials and assure device supply. Through partnerships with more than 30 partner depots, the company can provide a full range of services for clinical trials.
Parexel
Parexel Clinical Research Organization is a clinical research organization with premium facilities located around the globe. Its network of research centers features an extensive database of patient populations and experienced local professionals. In addition, all of the research centers operate under standardized protocols and SOPs. The company’s global presence makes it a perfect partner for global studies.
Parexel has a proven track record for developing new therapies. The organization’s expertise allows it to develop and deliver novel drugs with unprecedented speed. It has participated in development of more than half of the top 50 drugs of the first decade of the 21st century. Its commitment to research and innovation has earned Parexel the status of a leading global clinical research organization.
Parexel’s commitment to research has led it to create an innovative program that will integrate clinical research into a community healthcare setting. This initiative will increase diversity in clinical trials by increasing access to diverse patient populations. In addition, it will help Parexel’s biopharmaceutical customers expand their reach into new communities.
The firm has also been criticized for the practices that it followed during a clinical trial conducted at the Northwick Park Hospital in London. Ultimately, six test subjects developed permanent health problems as a result of the testing. While the company was eventually found to have operated within guidelines, the controversy sparked public interest in the CRO`s industry and increased the number of volunteers for clinical trials.
Parexel has significant expertise across the drug development process, with over five hundred employees in 37 countries. Its expertise includes biostatics, clinical pharmacology, data management, and regulatory consulting. It also offers comprehensive outsourced clinical trials, including phase II and III trials, and market access and commercialization.
